应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
02509 荃信生物-B
已收盘 10-21 16:08:20
16.740
+0.540
+3.33%
最高
16.740
最低
15.870
成交量
4.28万
今开
16.200
昨收
16.200
日振幅
5.37%
总市值
37.33亿
流通市值
37.33亿
总股本
2.23亿
成交额
70.19万
换手率
0.02%
流通股本
2.23亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
荃信生物-B更新9月股份变动月报表，股本维持稳定
公告速递 · 10-07
荃信生物-B更新9月股份变动月报表，股本维持稳定
荃信生物-B（02509）：奥托奇拜单抗结节性痒疹III期临床成功 两项适应症III期均达终点
金吾财讯 · 10-02
荃信生物-B（02509）：奥托奇拜单抗结节性痒疹III期临床成功 两项适应症III期均达终点
荃信生物-B（02509）公布奥托奇拜单抗治疗结节性痒疹III期临床数据 计划2026年内申报上市
公告速递 · 10-02
荃信生物-B（02509）公布奥托奇拜单抗治疗结节性痒疹III期临床数据 计划2026年内申报上市
荃信生物-B(02509.HK)：奥托奇拜单抗(QX005N)结节性痒疹III期临床研究成果于EADV 2026以突破性研究口头报告形式发布
智通财经 · 10-02
荃信生物-B(02509.HK)：奥托奇拜单抗(QX005N)结节性痒疹III期临床研究成果于EADV 2026以突破性研究口头报告形式发布
荃信生物－Ｂ(02509.HK)：余熹辞任非执行董事
中金财经 · 09-22
荃信生物－Ｂ(02509.HK)：余熹辞任非执行董事
荃信生物-B（02509）上调QX001S框架协议2026-2028年度交易上限 余熹辞任、提名季娟任非执行董事
公告速递 · 09-22
荃信生物-B（02509）上调QX001S框架协议2026-2028年度交易上限 余熹辞任、提名季娟任非执行董事
荃信生物-B(02509.HK)：季娟获提名为非执行董事
智通财经 · 09-22
荃信生物-B(02509.HK)：季娟获提名为非执行董事
荃信生物-B 2026年中期营收42.41亿元，经调整净利润20.25亿元
公告速递 · 09-21
荃信生物-B 2026年中期营收42.41亿元，经调整净利润20.25亿元
港股异动 | 荃信生物-B(02509)早盘涨超9% BD成果集中兑现 首款产品商业化放量
智通财经 · 09-14
港股异动 | 荃信生物-B(02509)早盘涨超9% BD成果集中兑现 首款产品商业化放量
荃信生物-B 8月无新增发行或股份变动
公告速递 · 09-04
荃信生物-B 8月无新增发行或股份变动
自免龙头兑现长期主义：荃信生物（02509）营收翻倍背后的“双引擎”逻辑
智通财经 · 08-21
自免龙头兑现长期主义：荃信生物（02509）营收翻倍背后的“双引擎”逻辑
荃信生物-B(02509)发布中期业绩 股东应占溢利2.03亿元 同比扭亏为盈 “荃信1.0”布局已基本成型
智通财经 · 08-19
荃信生物-B(02509)发布中期业绩 股东应占溢利2.03亿元 同比扭亏为盈 “荃信1.0”布局已基本成型
荃信生物-B（02509）2026年中期收入4.24亿元 由亏转盈录得1.99亿元净利润
公告速递 · 08-19
荃信生物-B（02509）2026年中期收入4.24亿元 由亏转盈录得1.99亿元净利润
荃信生物-B（02509）拟于8月19日召开董事会审议2026年中期业绩
公告速递 · 08-07
荃信生物-B（02509）拟于8月19日召开董事会审议2026年中期业绩
荃信生物-B发布7月股份变动月报，股本维持227,071,600元
公告速递 · 08-06
荃信生物-B发布7月股份变动月报，股本维持227,071,600元
荃信生物：QX027N注射液两项适应症获临床试验许可
财中社 · 07-31
荃信生物：QX027N注射液两项适应症获临床试验许可
荃信生物-B（02509）长效双抗QX027N获COPD及CRSwNP临床试验默示许可
公告速递 · 07-31
荃信生物-B（02509）长效双抗QX027N获COPD及CRSwNP临床试验默示许可
荃信生物-B（02509.HK）旗下QX027n获两项临床试验批件，剑指COPD与慢性鼻窦炎
美股速递 · 07-31
荃信生物-B（02509.HK）旗下QX027n获两项临床试验批件，剑指COPD与慢性鼻窦炎
荃信生物-B(02509.HK)：QX027N获得慢性阻塞性肺疾病及慢性鼻窦炎伴鼻息肉两项适应症的临床试验默示许可
智通财经 · 07-31
荃信生物-B(02509.HK)：QX027N获得慢性阻塞性肺疾病及慢性鼻窦炎伴鼻息肉两项适应症的临床试验默示许可
荃信生物-B(02509)合作伙伴Caldera Therapeutics拟与Synlogic合并登陆纳斯达克 并同步募资 2.78 亿美元
智通财经 · 07-29
荃信生物-B(02509)合作伙伴Caldera Therapeutics拟与Synlogic合并登陆纳斯达克 并同步募资 2.78 亿美元
暂无数据
公司概况
公司名称：
荃信生物-B
所属市场：
SEHK
上市日期：
--
主营业务：
江苏荃信生物医药股份有限公司是一家主要从事自身免疫及过敏性疾病的生物疗法研发、制造及商业化的中国公司。该公司专注于皮肤、风湿、呼吸道及消化道疾病。该公司的产品主要包括赛乐信、奥托奇拜单抗，以及鲁塞奇塔单抗等。该公司在国内和国外市场开展业务。
发行价格：
--
{"stockData":{"symbol":"02509","market":"HK","secType":"STK","nameCN":"荃信生物-B","latestPrice":16.74,"timestamp":1792570100002,"preClose":16.2,"halted":0,"volume":42800,"delay":0,"changeRate":0.033333333333333284,"floatShares":223000000,"shares":223000000,"eps":1.41,"marketStatus":"已收盘","change":0.54,"latestTime":"10-21 16:08:20","open":16.2,"high":16.74,"low":15.87,"amount":701894,"amplitude":0.053704,"askPrice":16.92,"askSize":4800,"bidPrice":16.74,"bidSize":800,"shortable":3,"etf":0,"ttmEps":2.802943,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792632600000},"marketStatusCode":5,"adr":0,"listingDate":1710864000000,"exchange":"SEHK","adjPreClose":16.2,"openAndCloseTimeList":[[1792546200000,1792555200000],[1792558800000,1792569600000]],"volumeRatio":0.141816,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02509/tweets","defaultTab":"tweets","newsList":[{"id":"1199511409","title":"荃信生物-B更新9月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1199511409","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199511409?lang=zh_cn&edition=full","pubTime":"2026-10-07 17:01","pubTimestamp":1791363707,"startTime":"0","endTime":"0","summary":"江蘇荃信生物醫藥股份有限公司于2026年10月7日发布截至2026年9月30日的证券变动月报表。本次公告显示，公司在报告期内未有新增发行、购回或注销股份，整体股本维持不变。截至2026年9月30日，荃信生物-B在维持足够公众持股量方面符合香港联交所《上市规则》及其他适用监管规定。公司确认本月所有股份事宜均已遵守相关法律规定并通过董事会获正式批准。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672932687","title":"荃信生物-B（02509）：奥托奇拜单抗结节性痒疹III期临床成功 两项适应症III期均达终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2672932687","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2672932687?lang=zh_cn&edition=full","pubTime":"2026-10-02 09:05","pubTimestamp":1790903106,"startTime":"0","endTime":"0","summary":"金吾财讯 | 荃信生物-B 发布公告，旗下奥托奇拜单抗治疗结节性痒疹的中国III期临床研究成果，于EADV 2026年会以突破性研究口头报告发布。该项多中心、随机双盲、安慰剂对照试验在国内62个中心入组412名中重度结节性痒疹成人患者。QX005N靶向IL-4Rα，其结节性痒疹、特应性皮炎两项适应症III期临床均成功达到主要终点，公司计划2026年内提交新药上市申请。","market":"sh","thumbnail":"https://static.szfiu.com/news/20200915/NjdlOTQyZDE5NzA3MzU4ZTU3YTk2ZGQ0MjAwMDE4NjcyODIz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/NjdlOTQyZDE5NzA3MzU4ZTU3YTk2ZGQ0MjAwMDE4NjcyODIz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992902","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107962046","title":"荃信生物-B（02509）公布奥托奇拜单抗治疗结节性痒疹III期临床数据 计划2026年内申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1107962046","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107962046?lang=zh_cn&edition=full","pubTime":"2026-10-02 08:11","pubTimestamp":1790899908,"startTime":"0","endTime":"0","summary":"2026年10月2日，江苏荃信生物医药股份有限公司发布自愿公告称，旗下以IL-4Rα为靶点的创新型人源化单克隆抗体奥托奇拜单抗治疗结节性痒疹的中国III期临床研究成果入选第35届欧洲皮肤病与性病学会年会“突破性研究进展”环节，并以口头报告形式对外发布。荃信生物-B表示，奥托奇拜单抗用于结节性痒疹和特应性皮炎的III期临床试验均已达到主要终点，公司计划于2026年内向监管机构递交新药上市申请。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672984767","title":"荃信生物-B(02509.HK)：奥托奇拜单抗(QX005N)结节性痒疹III期临床研究成果于EADV 2026以突破性研究口头报告形式发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2672984767","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2672984767?lang=zh_cn&edition=full","pubTime":"2026-10-02 08:06","pubTimestamp":1790899568,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669451128","title":"荃信生物－Ｂ(02509.HK)：余熹辞任非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2669451128","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669451128?lang=zh_cn&edition=full","pubTime":"2026-09-22 22:37","pubTimestamp":1790087824,"startTime":"0","endTime":"0","summary":"格隆汇9月22日丨荃信生物－Ｂ(02509.HK)宣布，余熹因工作安排变动，已提呈辞任公司非执行董事及战略与发展委员会成员职务，其辞任于本公告发布之日生效。余熹辞任后，董事会已决议提名季娟为公司非执行董事，任期自相关决议案于公司临时股东大会审议及批准之日起至第二届董事会任期届满为止，就此将于临时股东大会上提呈一项普通决议案，以供股东审议及批准，且季娟于其任期届满后符合资格膺选连任。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260922/32378289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152697930","title":"荃信生物-B（02509）上调QX001S框架协议2026-2028年度交易上限 余熹辞任、提名季娟任非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=1152697930","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152697930?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:35","pubTimestamp":1790084139,"startTime":"0","endTime":"0","summary":"9月22日，荃信生物-B发布公告，公司董事会拟根据与杭州中美华东制药有限公司签订的QX001S框架协议，调高2026年至2028年三个财年下的持续关连交易年度上限，同时公布董事会人员变动事项。董事会同时宣布，余熹先生因工作安排变动，已于9月22日辞任非执行董事及战略与发展委员会成员职务。荃信生物-B是一家专注于自身免疫及过敏性疾病生物疗法的生物科技公司；中美华东为公司主要股东，并负责QX001S的联合开发及独家商业化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669147485","title":"荃信生物-B(02509.HK)：季娟获提名为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2669147485","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669147485?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:35","pubTimestamp":1790084139,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127803268","title":"荃信生物-B 2026年中期营收42.41亿元，经调整净利润20.25亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1127803268","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127803268?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:43","pubTimestamp":1789980185,"startTime":"0","endTime":"0","summary":"据荃信生物-B公告，截至2026年6月30日，公司实现营收42.41亿元，同比增加约105.36%。期内经调整后净利润20.25亿元，较上年同期亏损0.05亿元实现扭亏为盈。期间公司毛利约为37.13亿元，同比增加约109.22%；毛利率由上年同期的约85.9%微升至约87.6%，显示整体盈利能力进一步增强。经营活动产生的现金流入2829万元，上年同期则为净流出，亦实现转正。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"荃信生物-B 2026年中期营收42.41亿元，经调整净利润20.25亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667344836","title":"港股异动 | 荃信生物-B(02509)早盘涨超9% BD成果集中兑现 首款产品商业化放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2667344836","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667344836?lang=zh_cn&edition=full","pubTime":"2026-09-14 10:55","pubTimestamp":1789354544,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荃信生物-B早盘涨超9%。截至发稿，涨5.60%，报17.15港元，成交额2670.93万港元。消息面上，荃信生物中期财报显示，公司BD成果集中兑现。华创证券指出，\"荃信1.0\"单抗产品布局成果逐步显现。首个商业化产品乌司奴单抗生物类似药赛乐信/赛捷宁销售势头强劲，其商业化伙伴在2026年上半年录得国内销售额逾3亿元，已超过去年全年水平，公司从中获得的产品供应及利润分成总收入超过4950万元；5月，克罗恩病适应症获批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495482.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","KCAI","VXUS","02509","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186156655","title":"荃信生物-B 8月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1186156655","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186156655?lang=zh_cn&edition=full","pubTime":"2026-09-04 10:10","pubTimestamp":1788487839,"startTime":"0","endTime":"0","summary":"江蘇荃信生物醫藥股份有限公司于2026年9月4日披露了截至2026年8月31日的证券变动月报表，显示公司本月未发生新增发行或购回股份等变动，股本维持稳定。报告指出，荃信生物-B当前法定注册股本总额为人民币227,071,600元，每股面值人民币1元，与上月保持一致。月内并无新增或减少股份，公司也无股份期权、股权激励计划及可转换债券等方面的变动。本次月报由董事会秘书和联席公司秘书胡衍保签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661825085","title":"自免龙头兑现长期主义：荃信生物（02509）营收翻倍背后的“双引擎”逻辑","url":"https://stock-news.laohu8.com/highlight/detail?id=2661825085","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661825085?lang=zh_cn&edition=full","pubTime":"2026-08-21 14:53","pubTimestamp":1787295187,"startTime":"0","endTime":"0","summary":"在此背景下，专注于自免领域的荃信生物2026年中期交出里程碑答卷，不仅印证了商业化兑现能力，更凸显了其全球化布局的战略成效。从核心财务数据来看，荃信生物在2026年上半年展现出强劲的增长势能。在智通财经APP看来，商业化基本盘的稳固与爆发，是支撑荃信生物业绩高增的关键引擎。在稳固国内基本盘的同时，荃信生物的出海合作项目也正迎来密集兑现期。展望未来，荃信生物的管线梯队正加速走向收获期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"自免龙头兑现长期主义：荃信生物（02509）营收翻倍背后的“双引擎”逻辑","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660426865","title":"荃信生物-B(02509)发布中期业绩 股东应占溢利2.03亿元 同比扭亏为盈 “荃信1.0”布局已基本成型","url":"https://stock-news.laohu8.com/highlight/detail?id=2660426865","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660426865?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:29","pubTimestamp":1787146189,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B 发布截至2026年6月30日止6个月业绩，该集团期内取得收入4.24亿元人民币，同比增加105.37%;公司权益股东应占溢利2.03亿元，同比扭亏为盈;每股基本盈利0.91元。收入增加主要由于授权收入及QX001S利润分成增加所致。随着前述单抗产品在商业端和研发端的持续兑现，“荃信1.0”布局已基本成型。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120262738","title":"荃信生物-B（02509）2026年中期收入4.24亿元 由亏转盈录得1.99亿元净利润","url":"https://stock-news.laohu8.com/highlight/detail?id=1120262738","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120262738?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:26","pubTimestamp":1787145998,"startTime":"0","endTime":"0","summary":"2026年8月19日，荃信生物-B公布截至2026年6月30日止六个月未经审计中期业绩。期内，公司实现收入4.24亿元，同比增幅105.4%。授权收入3.79亿元，其中包括QX027N海外授权首付款及非现金对价、QX008N及QX031N里程碑款，以及QX001S合作协议利润分成收入40.4百万元；QX001S产品供应收入9.2百万元。销售成本为5,272.4万元，同比增加82.8%，主要受海外授权项目及CDMO服务成本增长影响。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108795750","title":"荃信生物-B（02509）拟于8月19日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1108795750","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108795750?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:36","pubTimestamp":1786091801,"startTime":"0","endTime":"0","summary":"江苏荃信生物医药股份有限公司（02509，以下简称“荃信生物-B”）8月7日公告称，公司董事会决定于2026年8月19日（星期三）召开会议，届时将审议并批准本集团截至2026年6月30日止六个月的中期业绩及其发布事宜，并处理其他相关事项。\n公告显示，截至公告日，公司董事会成员包括：董事会主席兼执行董事裘霽宛先生，执行董事吴亦亮先生及林伟栋先生；非执行董事余熹先生及吴志强先生；独立非执行董事冯志伟先生、邹忠梅博士及凌建群博士。\n公司表示，香港交易及结算所有限公司及香港联合交易所有限公司对本公告内容概不负责，并不对其准确性或完整性作出任何声明，也不承担因依赖该公告内容而引致的任何损失责任。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166349659","title":"荃信生物-B发布7月股份变动月报，股本维持227,071,600元","url":"https://stock-news.laohu8.com/highlight/detail?id=1166349659","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166349659?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:00","pubTimestamp":1786003254,"startTime":"0","endTime":"0","summary":"荃信生物-B于2026年8月6日披露了截至2026年7月31日止的月度证券变动报告。公告显示，公司法定注册股本维持227,071,600元，与上月末一致。本月内，荃信生物-B普通股H股已发行股份由上月底结存的223,381,800股下降至223,369,200股，减少12,600股；同时公司库存股份增加12,600股，从3,689,800股升至3,702,400股。公司确认上述变动后已发行股份总数继续维持在227,071,600股不变。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655636655","title":"荃信生物：QX027N注射液两项适应症获临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2655636655","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655636655?lang=zh_cn&edition=full","pubTime":"2026-07-31 20:01","pubTimestamp":1785499260,"startTime":"0","endTime":"0","summary":"7月31日，荃信生物（02509）发布公告，近日，公司自主研发的长效双抗QX027N注射液获得中国国家药品监督管理局药品审评中心的临床试验默示许可，分别拟用于治疗慢性阻塞性肺疾病及慢性鼻窦炎伴鼻息肉。这次获批是QX027N继特应性皮炎及哮喘后新增的两项呼吸系统相关适应症。公司将加快该候选药物的临床开发节奏，以巩固在相关领域的领先优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607313828550155.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607313828550155.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02509","BMED","PSYK","MDTX","BK1161","IBBQ","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199457602","title":"荃信生物-B（02509）长效双抗QX027N获COPD及CRSwNP临床试验默示许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1199457602","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199457602?lang=zh_cn&edition=full","pubTime":"2026-07-31 19:20","pubTimestamp":1785496838,"startTime":"0","endTime":"0","summary":"2026年7月31日，江蘇荃信生物醫藥股份有限公司发布自愿公告称，其自主研发的长效双特异性单克隆抗体QX027N注射液已获得中国国家药品监督管理局药品审评中心临床试验默示许可，拟用于治疗慢性阻塞性肺疾病和慢性鼻窦炎伴鼻息肉，受理号分别为CXSL2600561和CXSL2600560。该项目在特应性皮炎及哮喘之后新增两项呼吸系统相关适应症。公司介绍，该候选药物旨在为哮喘、COPD、AD及CRSwNP等免疫炎症类疾病提供更深层次且更持久的疾病控制。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156603396","title":"荃信生物-B（02509.HK）旗下QX027n获两项临床试验批件，剑指COPD与慢性鼻窦炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1156603396","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156603396?lang=zh_cn&edition=full","pubTime":"2026-07-31 19:18","pubTimestamp":1785496736,"startTime":"0","endTime":"0","summary":"荃信生物-B（QYUNS-B）近日宣布，其研发管线中的核心产品——QX027n，已成功获得两项临床试验批准。这两项批件分别针对慢性阻塞性肺疾病（COPD）以及慢性鼻窦炎两大适应症。\n这一进展标志着该药物在呼吸系统及耳鼻喉领域迈出了关键一步。COPD作为一种常见且严重的肺部疾病，患者群体庞大；而慢性鼻窦炎同样困扰着数以百万计的人群，治疗方案仍有待优化。QX027n若能在此两个领域取得突破，无疑将为患者带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655363591","title":"荃信生物-B(02509.HK)：QX027N获得慢性阻塞性肺疾病及慢性鼻窦炎伴鼻息肉两项适应症的临床试验默示许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2655363591","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655363591?lang=zh_cn&edition=full","pubTime":"2026-07-31 19:18","pubTimestamp":1785496712,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655860380","title":"荃信生物-B(02509)合作伙伴Caldera Therapeutics拟与Synlogic合并登陆纳斯达克 并同步募资 2.78 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655860380","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655860380?lang=zh_cn&edition=full","pubTime":"2026-07-29 20:06","pubTimestamp":1785326788,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B 公布，于2026年7月29日，公司合作伙伴Caldera Therapeutics,Inc与Synlogic,Inc.订立最终合并协议，以进行全股票交易合并。该合并将通过Caldera Therapeutics及Synlogic成为一家新成立的控股公司的全资附属公司而实现。完成后，合并并后的公司将以Caldera Therapeutics,Inc.的名称营运，并预期于纳斯达克资本市场以股票代码“CALD”进行交易。该私募融资仅由CalderaTherapeutics完成。Synlogic股东于拟议合并完成时将拥有的合并后公司所有权百分比将根据Synlogic于紧接完成日期前的估计现金净额进行调整。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473708.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SYBX","BK1161","02509","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.qyuns.net","stockEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0328},{"period":"3month","weight":0.0169},{"period":"6month","weight":-0.1025},{"period":"1year","weight":-0.4433},{"period":"ytd","weight":-0.1374}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":-0.0357},{"period":"3month","weight":-0.0412},{"period":"6month","weight":-0.079},{"period":"1year","weight":-0.077},{"period":"ytd","weight":-0.0688}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏荃信生物医药股份有限公司是一家主要从事自身免疫及过敏性疾病的生物疗法研发、制造及商业化的中国公司。该公司专注于皮肤、风湿、呼吸道及消化道疾病。该公司的产品主要包括赛乐信、奥托奇拜单抗，以及鲁塞奇塔单抗等。该公司在国内和国外市场开展业务。","exchange":"SEHK","name":"荃信生物-B","nameEN":"QYUNS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荃信生物-B(02509)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荃信生物-B(02509)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荃信生物-B,02509,荃信生物-B股票,荃信生物-B股票老虎,荃信生物-B股票老虎国际,荃信生物-B行情,荃信生物-B股票行情,荃信生物-B股价,荃信生物-B股市,荃信生物-B股票价格,荃信生物-B股票交易,荃信生物-B股票购买,荃信生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荃信生物-B(02509)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荃信生物-B(02509)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}